Healthy Living

Canadians Now Have More Options to Treat Hodgkin Lymphoma

Drug interactions and adverse reactions from the placebo-controlled trial

Exposure to monomethyl auristatin E (MMAE) may be affected with use of CYP3A4 inhibitors or inducers or P-gp inhibitors.

Adverse Reactions

With two uncontrolled trials of ADCETRIS as single therapy in 160 patients with relapsed HL and sALCL, the most common adverse reactions include: neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough and vomiting.

In a placebo-controlled trial of ADCETRIS in 329 patients with a high risk of relapse of HL or progression post-auto-HSCT, the most common adverse reactions included: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.